Research programme: autologous stromal vascular cell therapy - Invigorcell

Drug Profile

Research programme: autologous stromal vascular cell therapy - Invigorcell

Latest Information Update: 31 Jan 2015

Price : $50

At a glance

  • Originator Invigorcell
  • Developer IntelliCell BioSciences
  • Class Cell therapies
  • Mechanism of Action Cell replacements; Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Diabetes mellitus

Most Recent Events

  • 27 Jan 2015 Invigorcell in-licenses technology of producing vascular fraction cells from Intellicell Biosciences
  • 27 Jan 2015 Early research in Diabetes mellitus in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top